Table 2.
Cost-effectiveness analysis of breast cancer screening using the multi-cohort (population level) approach
| 0 % discounta | 3 % discounta | |||||
|---|---|---|---|---|---|---|
| Mean | 95 % CI | Mean | 95 % CI | |||
| Screened population | ||||||
| Total costs (Million Euros) | 1,608.7 | 1,566.0 | 1,651.7 | 1,126.6 | 1,097.8 | 1,155.3 |
| Screening mammography costs | 55.3 | 55.2 | 55.5 | 55.3 | 55.2 | 55.5 |
| Screening diagnosis workup | 12.1 | 11.5 | 12.7 | 12.1 | 11.5 | 12.7 |
| Clinical cancers diagnosis workup | 26.1 | 25.2 | 27.0 | 18.3 | 17.6 | 18.9 |
| Treatment costs | 1,515.1 | 1,472.8 | 1,557.5 | 1,040.9 | 1,012.5 | 1,069.3 |
| QALYs | 8,845,493 | 8,828,791 | 8,862,195 | 6,696,959 | 6,684,899 | 6,709,019 |
| Unscreened population | ||||||
| Total costs (Million Euros) | 1,584.3 | 1,538.8 | 1,629.8 | 1,090.2 | 1,059.2 | 1,121.3 |
| Screening mammography costs | 0.00 | 0.00 | 0.00 | 0.0 | 0.0 | 0.0 |
| Screening diagnosis workup | 0.00 | 0.00 | 0.00 | 0.0 | 0.0 | 0.0 |
| Clinical cancers diagnosis workup | 30.2 | 29.2 | 31.11 | 22.2 | 21.5 | 22.9 |
| Treatment costs | 1,554.1 | 1,509.0 | 1,599.24 | 1,068.0 | 1,037.3 | 1,098.8 |
| QALYs | 8,834,785 | 8,818,066 | 8,851,504 | 6,688,293 | 6,676,240 | 6,700,347 |
| Difference (Screened - Unscreened) | ||||||
| Total costs (Million Euros) | 24.4 | 8.5 | 40.3 | 36.4 | 24.6 | 1,557.5 |
| Screening mammography costs | 55.3 | 55.2 | 55.5 | 55.3 | 55.2 | 55.5 |
| Screening diagnosis workup | 12.1 | 11.5 | 12.7 | 12.1 | 11.5 | 12.7 |
| Clinical cancers diagnosis workup | −4.0 | −5.1 | −2.9 | −3.9 | −4.8 | −3.1 |
| Treatment costs | −39.0 | −54.8 | −23.1 | −27.1 | −38.9 | −15.4 |
| QALYs | 10,708 | 9,499 | 11,917 | 8,666 | 7,746 | 9,586 |
| ICER | 2,294 | 738 | 3,850 | 4,214 | 2,703.41 | 5,725 |
CI confidence interval, QALY quality-adjusted life years, ICER incremental cost-effectiveness ratio
aDiscount applied beginning from the end of the evaluated period until death